[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100505447":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":50,"collaborators":11,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":11,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":11,"enrollmentInfo":63,"targetDuration":11,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":11,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Amsterdam UMC, location VUmc","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Upfront repeat local treatment","ACTIVE_COMPARATOR",null,[13],"Other: Repeat local treatment",{"label":15,"type":16,"description":11,"interventionNames":17},"Neoadjuvant systemic therapy followed by repeat local treatment","EXPERIMENTAL",[18,13],"Drug: Neoadjuvant systemic therapy (CAPOX+\u002F-B FOLFOX+\u002F-B FOLFIRI+\u002F-B)",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Neoadjuvant systemic therapy (CAPOX+\u002F-B FOLFOX+\u002F-B FOLFIRI+\u002F-B)","Standard first line systemic treatment:\n\nCAPOX+\u002F-B FOLFOX+\u002F-B FOLFIRI+\u002F-B\n\nCAPOX 4x (12 weeks) FOLFOX\u002FFOLFIRI 6x (12 weeks)\n\nMaximum 4 cycles of CAPOX or 6 cycles of FOLFOX\u002FFOLFIRI +\u002F- bevacizumab regardless of the location of primary tumor or RAS\u002FBRAF mutation",[15],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Repeat local treatment","Choice of repeat local treatment is to the discretion of the local investigator, and may be selected on a per patient basis.\n\nThe safety, feasibility and preferred type of surgical resection(s) is at the discretion of the liver surgeon (whether or not combined with thermal ablation).\n\nThe safety, feasibility and preferred type of thermal ablation(s) is at the discretion of the interventional radiologist (whether or not combined with surgical resection).",[15,9],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"M Dijkstra","CONTACT","+31(0)204444444","interventieradiologie@vumc.nl",[36],{"facility":37,"status":38,"city":39,"state":11,"zip":11,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Amsterdam UMC","RECRUITING","Amsterdam","Netherlands","NL",{"type":43,"coordinates":44},"Point",[45,46],4.88969,52.37403,{"lat":46,"lon":45},[49],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","M.R. Meijerink","Prof. Dr.","100505447","phase-3-collision-relapse-trial-100505447",false,"NCT05861505","COLLISION RELAPSE Trial","COLLISION RELAPSE Trial - Recurrent Colorectal Liver Metastases: Repeat Local Treatment +\u002F- Neoadjuvant Systemic Therapy - a Phase III Prospective Randomized Controlled Trial","Inclusion criteria\n\n* Age \\>18 years\n* Good performance status (ECOG 0-2 \u002F\u002F ASA 1-3)\n* Histological documentation of primary colorectal tumor\n* Local treatment performed for initial CRLM\n* New recurrence ≤12 months\n* ≥1 locally treatable CRLM (resectable\\* and\u002For ablatable)\n* Total number of new CRLM ≤5\n* Chemo-naïve or history of response to CAPOX\u002FFOLFOX\u002FFOLRIRI\n* Life expectancy of at least 12 weeks\n* Adequate bone marrow, liver and renal function\n* Written informed consent Exclusion criteria\n* Extrahepatic disease\n* MSI\u002FdMMR\n* Radical local treatment unfeasible or unsafe (e.g. insufficient future liver volume)\n* Compromised liver function (e.g. signs of portal hypertension, INR \\> 1,5 without use of anticoagulants, ascites)\n* Uncontrolled infections (\\> grade 2 NCI-CTC version 3.0)\n* Pregnant or breast-feeding subjects\n* Immuno- or chemotherapy ≤ 6 weeks prior to the randomization\n* Severe allergy to contrast media not controlled with premedication\n* Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results\n\nECOG = Eastern Cooperative Oncology Group, ASA = American Society of Anesthesiologists, MSI = Microsatellite instability, dMMR = deficient mismatch repair\n\n\\* Resection for resectable lesions considered possible obtaining negative resection margins (R0) and preserving adequate liver reserve","ALL","18 Years",{"count":64,"type":65},360,"ESTIMATED","INTERVENTIONAL",[68],"PHASE3","The primary objective is to demonstrate superiority of neoadjuvant systemic therapy followed by repeat local treatment as compared to upfront repeat local treatment in patients with at least one locally treatable recurrent CRLM in the absence of extrahepatic disease.",[71,72,73,74,75,76],"Colorectal Cancer","Liver Metastases","Liver Metastasis Colon Cancer","Chemotherapy Effect","Surgery","Recurrence","2023-05-05",{"date":79,"type":80},"2023-05-17","ACTUAL",{"date":82,"type":80},"2023-04-24",{"date":84,"type":65},"2028-05-01",{"name":5,"class":6},1]